QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 btig-maintains-buy-on-irhythm-technologies-raises-price-target-to-195

BTIG analyst Ryan Zimmerman maintains iRhythm Technologies (NASDAQ:IRTC) with a Buy and raises the price target from $190 to...

 baird-maintains-outperform-on-irhythm-technologies-raises-price-target-to-220

Baird analyst Mike Polark maintains iRhythm Technologies (NASDAQ:IRTC) with a Outperform and raises the price target from $1...

 citigroup-maintains-buy-on-irhythm-technologies-raises-price-target-to-205

Citigroup analyst Joanne Wuensch maintains iRhythm Technologies (NASDAQ:IRTC) with a Buy and raises the price target from $1...

 evercore-isi-group-maintains-in-line-on-irhythm-technologies-lowers-price-target-to-175

Evercore ISI Group analyst Vijay Kumar maintains iRhythm Technologies (NASDAQ:IRTC) with a In-Line and lowers the price targ...

 goldman-sachs-maintains-neutral-on-irhythm-technologies-raises-price-target-to-180

Goldman Sachs analyst David Roman maintains iRhythm Technologies (NASDAQ:IRTC) with a Neutral and raises the price target fr...

 canaccord-genuity-maintains-buy-on-irhythm-technologies-raises-price-target-to-193

Canaccord Genuity analyst William Plovanic maintains iRhythm Technologies (NASDAQ: IRTC) with a Buy and raises the price tar...

 evercore-isi-group-initiates-coverage-on-irhythm-technologies-with-in-line-rating-announces-price-target-of-185

Evercore ISI Group analyst Vijay Kumar initiates coverage on iRhythm Technologies (NASDAQ:IRTC) with a In-Line rating and an...

 irhythms-zio-home-based-monitoring-shows-faster-afib-diagnosis-in-amalfi-trial-esc-2025-and-jama-publication-highlight-results

Oxford University-led AMALFI clinical trial results presented at the European Society of Cardiology (ESC) Congress 2025 and pub...

 needham-maintains-buy-on-irhythm-technologies-raises-price-target-to-193

Needham analyst David Saxon maintains iRhythm Technologies (NASDAQ:IRTC) with a Buy and raises the price target from $180 to...

 citigroup-maintains-buy-on-irhythm-technologies-raises-price-target-to-183

Citigroup analyst Joanne Wuensch maintains iRhythm Technologies (NASDAQ:IRTC) with a Buy and raises the price target from $1...

 investor-short-report-flags-steep-downside-risk-for-irhythm-technologies-corrected

Spruce Point Capital warned iRhythm Technologies could face a 40%–70% stock decline, citing regulatory risks and product safety...

 b-of-a-securities-initiates-coverage-on-irhythm-technologies-with-buy-rating-announces-price-target-of-200

B of A Securities initiates coverage on iRhythm Technologies (NASDAQ:IRTC) with a Buy rating and announces Price Target of $200.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION